Toretrospectively investigate prevalence and characteristics of Diffusion-weighted b2000 negative images of histologically proven Gleason > or = 7 prostate adenocarcinomas. BACKGROUND: Prostate cancer is a 4th most common of all cancer and the most common in men adults with a mean age of diagnosis of 72-74 years old. Results of autopsy studies suggest that most men over 85 years old have latent PCa disease. However, Prostate Cancer has a very good prognosis with a 15-years relative survival of 91% (1). Prostatic MR is routinely used...

RETROSPECTIVE STUDY (Table1).: From May 2011 through September 2012: 63 patients with elevated PSA underwent prostatic MR imaging examination at 3.0-T without endorectal coil including b2000 value DWI sequence study prior to histological examination. They all presented at least one focal prostate cancer (Focal PCa) Gleason > or = 7. The diagnosis was assessed histopathologically after surgical resection (n=98) or TRUS-guided prostate biopsy (n=168) analysis. 29 (46%) patients had Radical prostatectomy and TRUS-guided biopsy, 2 patients (3%) had radical prostatectomy alone and 32 (51%) had...

PATHOLOGICAL RESULTS (Table2): 63 patients with 200 prostate cancer foci Mean prostate cancer foci size on DWMR Images was 8.37 mm ± 7.79mm (SD), range: 4 mm – 28 mm Mean prostate cancer foci size on TRUS-guided biopsy was 8.93 mm ± 9.88mm (SD), range: 0.4 mm – 59 mm Mean tumour-to- parenchyma ratio was 30.75% ± 26.85% (SD) range 0.78% – 96% Localisations and are Gleason’s grade repartition are reported in Table 2. Table 2. Characteristics of the population Gleason’s grade DWI size (mm)...

We reported 84.8% IC95 [81.7% - 87.9%] of Gleason 7 Focal PCa detection and only 27% for Gleason 6 Focal Pca detection, those results were consistent with the results of other researchers (4) with conventional DWI with ADC cartography alone (5,6) and this is equivalent to DWI associated with T2 (3,5,7). Eyeball assessement of DW MR sequences using a b value of 2000sec/mm2 is a fast and reliable technique to detect more than 5mm significant tumoral foci containing Gleason 4 components. Most invisible lesion are...

1.Grönberg H. Prostate cancer epidemiology. Lancet 2003 8;361:859-64. 2.Lemaitre L, Rouvière O, Penna-Renard R, Villers A, Puech P. MRI and prostate cancer: a paradigm shift, J Radiol 2008;89:1053-63. 3. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Lagager V, Fütterer JJ. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-57. 4. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO. Initial experience with identifying high-grade prostate cancer...

Matthias BARRAL (MD), Currently Department of Body Imaging, Hopital Foch, 92400 Suresnes, France. [email protected] Antoine SCHERRER (MD),Department of Body Imaging, Hopital Foch, 92400Suresnes, France. [email protected] Xavier BELIN(MD),Department of Body Imaging, Hopital Foch, 92400Suresnes, France. [email protected] François MELLOT(MD),Department of Body Imaging, Hopital Foch, 92400Suresnes, France. [email protected] Yann NEUZILLET (MD), Department of Urology,Hopital Foch, 92400Suresnes, France. [email protected]